Dexamethasone otoprotection in a multidose cisplatin ototoxicity mouse model.
OBJECTIVE
To develop a murine model for multidose administration of cisplatin that produces significant hearing threshold elevations and to use this model to assess the protective properties of intratympanic (IT) dexamethasone against cisplatin ototoxicity.


METHODS
Controlled repeated measures design.


METHODS
Translational research laboratory.


METHODS
Intraperitoneal (IP) cisplatin, 2 or 3 mg/kg/day, was administered for a total of 5 or 10 days in young CBA/J mice. Pure-tone evoked auditory brainstem response (ABR) thresholds were performed on days 7, 14, 21, and 28 to evaluate hearing threshold shifts. After development of the optimal dosing regimen, 15 mice received IT dexamethasone (24 mg/ml) in one ear and IT saline in the contralateral ear.


RESULTS
Significant threshold elevations were obtained for the 2 and 3 mg/kg/day 10 day groups, but both had high mortality rates and were excluded as potential multidose murine models. The 3 mg/kg/day 5 day group had a lower mortality rate and significant ABR threshold elevations for all frequencies on days 7, 14, 21, and 28. Using this dosing model, no statistically significant difference between IT dexamethasone and saline treated ears was found.


CONCLUSIONS
Unlike previous single dose models, IT dexamethasone did not have an otoprotective effect in a multidose murine model of cisplatin ototoxicity.
University of Connecticut Health Center, Department of Surgery, Division of Otolaryngology-Head & Neck Surgery, Farmington, Connecticut, USA.
Amy Lawrason
AL
Hughes
Nighat
N
Hussain
Ryan
R
Pafford
Kourosh
K
Parham
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity*; D001309:Auditory Threshold / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity*; D003907:Dexamethasone / Q000627:therapeutic use*; D004195:Disease Models, Animal; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D007263:Infusions, Parenteral; D051379:Mice; D008808:Mice, Inbred CBA
D000970:Antineoplastic Agents; D005938:Glucocorticoids; D003907:Dexamethasone; D002945:Cisplatin
cisplatin; murine model; ototoxicity; sensorineural hearing loss